Merck Reports Updated Results of Keytruda (pembrolizumab) in P-III KEYNOTE-062 Study as a Monotherapy for 1L Treatment of Advanced Gastric Cancer

Shots:

• The P-III KEYNOTE-062 (NCT02494583) study involves assessing of Keytruda as monothx. and in combination with CT (cisplatin/5-fluorouracil/capecitabine) & CT as monthx. in 763 patients for the 1L treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma
• The P-III KEYNOTE-062 results: as monothx. met its 1EPs, noninferior to CT; as a combination therapy, no superiority for OS & PFS compare to CT as monothx.; no new safety signals observed; presented at ASCO on Jun 02, 2019
• Keytruda (pembrolizumab, IV, 100mg) is a mAb blocking the interaction between PD-1 and its ligands, PD-L1 and PD-L2 and activating the T lymphocytes and is evaluated in 950+ trials for multiple indications

Click here to read full press release/ article | Ref: Merck | Image: Caixin Global